Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials Article

sustainable development goals

publication date

  • May 2, 2024

webpage

published in

start page

  • 836

end page

  • 845

volume

  • 190

issue

  • 6